Two Transgenic Mouse Facilities are available to OSUCCC members. OSUCCC intends to supplement existing facilities at the OSU Biotechnology Center (OSUBC) and the Children's Hospital Research Foundation (CHRF) to increase their capacity to meet the requirements of Cancer Center members for transgenic animals. This avoids the substantial additional costs and the duplication of effort of establishing a third transgenic animal facility. The state-of-the-art OSUBC facility produces transgenic mice by pronuclear injection. It also creates embryonic stem (ES) cell lines and chimeric animals derived from these lines. The current size of the facility is sufficient to house approximately 2,000 mice. It is anticipated that by late summer of 1995, the facility will have completed an expansion into neighboring Pressey Hall which will increase the capacity of the Facility to 10,000 mice. The CHRF Transgenic Facility is located on the lower level of the Wexner Institute for Pediatric Research. This facility has two dedicated animal rooms and one procedure room with a total capacity of approximately 2,000 animals. The facility is equipped with state-of-the-art environmental controls, surgical instruments, and monitoring equipment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-24
Application #
6268872
Study Section
Project Start
1998-07-01
Project End
1999-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sharpnack, Michael F; Chen, Bin; Aran, Dvir et al. (2018) Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine 27:167-175
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Bassett, Emily A; Palanichamy, Kamalakannan; Pearson, Mitchell et al. (2018) Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. Oncotarget 9:14597-14607
Trn?ný, Marek; Verhoef, Gregor; Dyer, Martin Js et al. (2018) A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica 103:1351-1358
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Kim, Miriam Y; Yu, Kyung-Rok; Kenderian, Saad S et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell 173:1439-1453.e19
Malpeli, Giorgio; Barbi, Stefano; Tosadori, Gabriele et al. (2018) MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget 9:29753-29771
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Li, Jingyi; Xu, Jie; Abruzzo, Lynne V et al. (2018) Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget 9:10987-10994

Showing the most recent 10 out of 2602 publications